We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Muscular Dystrophy Drug Co. Seeks To Stall Derivative Suit

Law360, Boston (June 13, 2018, 7:52 PM EDT) -- Solid Biosciences Inc. told a Massachusetts judge on Wednesday that a shareholder derivative lawsuit should be put on hold because it too closely resembles a securities class action proceeding in federal court, both of which contend the company lied about its leading drug candidate before an initial public offering.

Investors have swarmed to court since the company focused on treating Duchenne muscular dystrophy announced in March that its first clinical patient was hospitalized soon after receiving Solid's signature gene therapy. Regulators placed the drug on an...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.